首页> 外国专利> ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS

ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS

机译:含炔,叠氮化物和三唑类黄酮作为调节剂,用于癌症的多药耐药

摘要

A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-continaing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRPl-overexpressed cell line (2008/MRPl) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRPl- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRPl and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141 - 340 nM) of LCC6MDR cells, DOX (78 - 590 nM) and vincristine (82 - 550 nM) resistance of 2008/MRPl cells and topotecan resistance (0.9 - 135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRPl transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.
机译:通过一系列含类黄酮的叠氮化物(Az 1-15)和炔烃(Ac 1-17)的环加成反应,可以有效地构建三唑桥联的类黄酮二聚体化合物库。筛选这些三唑桥联的类黄酮二聚体及其前体炔烃和叠氮化物连续类黄酮在P-gp过表达的细胞系(LCC6MDR),MRP1过表达的细胞系(2008 / MRP1)和BCRP过表达的细胞系(HEK293 / R2和MCF7-MX100)。通常,它们显示出非常有前途的针对P-gp,MRP1和BCRP介导的耐药性的MDR逆转活性。而且,它们对各种转运蛋白显示出不同的选择性水平。总体而言,它们可分为用于P-gp,MRP1和BCRP转运蛋白的单选择,双选择和多选择调节剂。 EC50值可逆转LCC6MDR细胞的紫杉醇耐药性(141-340 nM),2008 / MRP1细胞的DOX(78-590 nM)和长春新碱(82-550 nM)耐药性以及HEK293 /的拓扑替康耐药性(0.9-135 nM) R2和MCF7-MX100细胞处于纳摩尔范围。重要的是,许多化合物在BCRP过表达的细胞系中显示的EC50为10 nM或低于10 nM,表明这些二价三唑比P-gp和MRP1转运蛋白更选择性地抑制BCRP转运蛋白。如其高治疗指数值所示,大多数二聚体是安全的MDR化学增敏剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号